Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

Silke Gillessen Sommer presents the phase III PEACE-3 trial results, which evaluated the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC. The ...

Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues - Beyond the Abstract ...

The advent of PSMA-based PET imaging has brought a transformative shift in the personalized management of prostate cancer (PCa), with increasing routine clinical utilization across different stages of ...

Avelumab, an anti-programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because ...

To investigate the expression of metabolism-related genes (MRGs) in kidney renal clear cell carcinoma (KIRC) and their association with patient prognosis, and to identify potential targets for ...

Patient stratification remains a challenge for optimal treatment of prostate cancer (PCa). This clinical heterogeneity implies intra-tumoural heterogeneity, with different prostate epithelial cell ...

Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current ...

Accurate grading and staging of non-muscle invasive bladder cancer (NMIBC) is critical for prognosis and treatment selection. The advent of digital pathology and artificial intelligence (AI) has ...

Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer ...

This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy.